| Methods |
Randomised controlled trial (method of randomisation unclear) open, parallel group. |
| Participants |
112 participants randomised and 81 completed this study.
Demographic data:
Values presented as mean (SD) or as appropriate ‐
Salmeterol group:
Age (years):45.5(14).
Sex (M:F):31:25.
Baseline FEV1(litres): 2.21(0.8).
Theophylline group:
Age : 47.9(16.7).
Sex : (M:F) : 37:18.
Baseline FEV1(litres): 2.10(0.6). |
| Interventions |
Salmeterol 50 mcg BD (MDI) and dose ‐adjusted slow release oral theophylline twice daily over 12 months. |
| Outcomes |
FVC, FEV1, PEF(am and pm), daytime and nocturnal asthma symptoms, daily rescue medication use, quality of life and adverse events. |
| Notes |
Method of randomisation not given. 31 participants were withdrawn during this study. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Adequate sequence generation? |
Unclear risk |
Information not available |
| Allocation concealment? |
Unclear risk |
Information not available |
